TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31994616

Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (HS) technique
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Physiotherapy (P) technique
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hypertonic saline + physiotherapy (HSP) technique
Number of subjects: 90

Group type: COMPARATOR
Intervention: Hypertonic saline (HS) technique
Number of subjects: 90
Study: 30300021

Group type: EXPERIMENTAL
Intervention: Combined laser with topical photo‐enhancer gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Solo laser treatment
Number of subjects: 20
Study: 29029097

Group type: EXPERIMENTAL
Intervention: 600 IU/d Vitamin D3
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: 1000 IU/d Vitamin D3
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: 2000 IU/d Vitamin D3
Number of subjects: 685

Group type: COMPARATOR
Intervention: Control (lower doses)
Number of subjects: 685
Study: 25892658

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (.08 mg/kg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 55
Study: 23356494

Group type: EXPERIMENTAL
Intervention: Intravenous iloprost after liver transplantation
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study: 21904779

Group type: EXPERIMENTAL
Intervention: Pentazocine (0.3 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl (1 μg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study: 18673303

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT) - 4 x 4 min intervals at 90% of maximal heart rate, each interval separated by 3 min at 70%, twice a week for 3 months
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Multidisciplinary Treatment Group (MTG) - exercise, dietary and psychological advice, twice a month for 12 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Multidisciplinary Treatment Group (MTG)
Number of subjects: 54
Study: 16805719

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose dexamethasone
Number of subjects: 0
Study: 15223085

Group type: EXPERIMENTAL
Intervention: Tramadol ER 100 mg QD (increased to 200 mg QD after 1 week, with further increases allowed up to 400 mg QD)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Tramadol ER
Number of subjects: 246
Study: 11421512

Group type: EXPERIMENTAL
Intervention: Powerbreathe training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 12
Study: 9292645

Group type: EXPERIMENTAL
Intervention: Copper intrauterine devices (IUDs)
Number of subjects: 1337
Study: 8417077

Group type: EXPERIMENTAL
Intervention: Learning group (2,500 patients)
Number of subjects: 4006

Group type: EXPERIMENTAL
Intervention: Model derived from learning group
Number of subjects: 4006
Study: 3018602

Group type: EXPERIMENTAL
Intervention: Enalapril plus hydrochlorothiazide
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard triple therapy (STT)
Number of subjects: 75
Study: 30519976

Group type: EXPERIMENTAL
Intervention: General practitioner‐led interprofessional medication assessment
Number of subjects: 512

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 512
Study: 28349727

Group type: EXPERIMENTAL
Intervention: β‐alanine group (6.4 g day‐1 of β‐alanine)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo group (6.4 g day‐1 of dextrose)
Number of subjects: 27
Study: 25449350

Group type: EXPERIMENTAL
Intervention: Target temperature management of 33 °C (TTM33)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Target temperature management of 36 °C (TTM36)
Number of subjects: 22
Study: 23065656

Group type: EXPERIMENTAL
Intervention: Enzastaurin (500 mg daily for 6 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 22016344

Group type: EXPERIMENTAL
Intervention: Nurse case management intervention for 6 weeks post-discharge, involving over 50 different nursing interventions (2-15 per person) targeting physical, emotional, psychological impairments, role participation restrictions, and health perception.
Number of subjects: 190

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 190
Study: 18840101

Group type: EXPERIMENTAL
Intervention: Interscalene plexus block
Number of subjects: 26

Group type: COMPARATOR
Intervention: General anesthesia only (Control)
Number of subjects: 26
Study: 17153886

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) with standardized P sylvestris pollen extract
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 35
Study: 14969156

Group type: EXPERIMENTAL
Intervention: Nitroglycerin 15 mg in slow-release form (N-15)
Number of subjects: 15
Study: 10711552

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel, 90 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intramuscular (IM) progesterone, 50 mg
Number of subjects: 14
Study: 8872685

Group type: EXPERIMENTAL
Intervention: Enflurane at MAC 0.5, 1.0, and 1.5
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isoflurane at MAC 0.5, 1.0, and 1.5
Number of subjects: 20
Study: 1739798

Group type: EXPERIMENTAL
Intervention: 10 minute appointments
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal rate appointments (median six minutes per patient)
Number of subjects: 16
Study: 6645520

Group type: EXPERIMENTAL
Intervention: Cognitive program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Values-clarification program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decision-making program
Number of subjects: 0
Study: 31187749

Group type: EXPERIMENTAL
Intervention: Cutting diathermy skin incision
Number of subjects: 64

Group type: COMPARATOR
Intervention: Scalpel skin incision
Number of subjects: 64
Study: 28619005

Group type: EXPERIMENTAL
Intervention: Immunonutrition (Group A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard enteral feed (Group B)
Number of subjects: 36
Study: 25494870

Group type: EXPERIMENTAL
Intervention: Marathon training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study: 23294143

Group type: EXPERIMENTAL
Intervention: Probiotic lozenges containing L. reuteri (ATCC55730 and ATCC PTA5289) taken twice a day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo lozenges taken twice a day
Number of subjects: 18
Study: 21680771

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Exercise control (bicycle endurance and stretching exercises)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Wait-listed control (usual medical care)
Number of subjects: 38
Study: 19623046

Group type: EXPERIMENTAL
Intervention: Ventilator-associated pneumonia risk score
Number of subjects: 1856

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation duration
Number of subjects: 1856

Group type: EXPERIMENTAL
Intervention: Calibration and discrimination tests
Number of subjects: 1856
Study: 16944194

Group type: EXPERIMENTAL
Intervention: Spirulina platensis
Number of subjects: 16
Study: 14747691

Group type: EXPERIMENTAL
Intervention: Black tea drinking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free living diet
Number of subjects: 0
Study: 11240881

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.04 mg.kg‐1 (1 mg.m‐2)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.1 mg.kg‐1 (2.5 mg.m‐2)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.2 mg.kg‐1 (5 mg.m‐2)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Overall Ondansetron (all doses)
Number of subjects: 131
Study: 8051642

Group type: EXPERIMENTAL
Intervention: GpA (scrubbing the operative site for ten minutes with an antiseptic)
Number of subjects: 135

Group type: COMPARATOR
Intervention: GpB (simplified method where antiseptic was painted onto the operation site)
Number of subjects: 135
Study: 3555055

Group type: EXPERIMENTAL
Intervention: Single-dose ciprofloxacin (500 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Three-day ciprofloxacin (500 mg twice daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Three-day trimethoprim-sulfamethoxazole (160 mg and 800 mg, respectively, twice daily)
Number of subjects: 40
Study: 31707100

Group type: EXPERIMENTAL
Intervention: Dietary choline intake (energy-adjusted)
Number of subjects: 1981

Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine intake
Number of subjects: 1981

Group type: EXPERIMENTAL
Intervention: Sphingomyelin intake
Number of subjects: 1981
Study: 29643158

Group type: EXPERIMENTAL
Intervention: Enhanced transtheoretical model of behaviour change in conjunction with physiotherapy
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard care (physiotherapy)
Number of subjects: 220
Study: 26372728

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 24991787

Group type: EXPERIMENTAL
Intervention: Low doses of statins
Number of subjects: 64

Group type: COMPARATOR
Intervention: Statin-free group
Number of subjects: 64
Study: 23690531

Group type: EXPERIMENTAL
Intervention: Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, Glucagon-like Peptide 1 Receptor Agonists, Insulin (added to metformin 1,000-2,000 mg/day)
Number of subjects: 5000
Study: 20300080

Group type: EXPERIMENTAL
Intervention: Alternate-day fasting (ADF) controlled feeding phase for 4 weeks
Number of subjects: 16
Study: 18836692

Group type: EXPERIMENTAL
Intervention: Calcium ascorbate with vitamin C metabolites
Number of subjects: 15

Group type: COMPARATOR
Intervention: Vitamin C alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Calcium ascorbate with vitamin C metabolites (two formulations)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 16415712

Group type: EXPERIMENTAL
Intervention: Intravenous clomipramine (CMI) 150 mg on day 1 and 200 mg on day 2, followed by oral CMI starting at 200 mg/d, increased by 25 mg every 4 days to 250 mg/d for 12 weeks.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Oral clomipramine (CMI) starting at 200 mg/d, increased by 25 mg every 4 days to 250 mg/d for 12 weeks.
Number of subjects: 34
Study: 15314994

Group type: EXPERIMENTAL
Intervention: Methizole (thiamazole)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Radioiodine (131 I)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Operative procedures
Number of subjects: 144
Study: 10653054

Group type: EXPERIMENTAL
Intervention: formoterol 12 microg + oxitropium bromide 600 microg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: formoterol 24 microg + oxitropium bromide 600 microg
Number of subjects: 20

Group type: COMPARATOR
Intervention: formoterol 12 microg
Number of subjects: 20

Group type: COMPARATOR
Intervention: formoterol 24 microg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: placebo + oxitropium bromide 600 microg
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo + placebo
Number of subjects: 20
Study: 8957981

Group type: EXPERIMENTAL
Intervention: Fuzzy logic control of mechanical ventilation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Manual ventilation control
Number of subjects: 30
Study: 8308942

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 0
Study: 3161529

Group type: EXPERIMENTAL
Intervention: Midazolam; repeated doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam; similar doses given with the same frequency
Number of subjects: 0
Study: 31104282

Group type: EXPERIMENTAL
Intervention: Biliopancreatic Limb (BPL) 70 cm
Number of subjects: 506

Group type: COMPARATOR
Intervention: Biliopancreatic Limb (BPL) 120 cm
Number of subjects: 506
Study: 28474984

Group type: EXPERIMENTAL
Intervention: CO inhalation (carboxyhemoglobin 22%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 27101726

Group type: EXPERIMENTAL
Intervention: Minimally invasive extracorporeal circulation (MECC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation (CECC)
Number of subjects: 200
Study: 24916371

Group type: EXPERIMENTAL
Intervention: Culturally sensitive couple‐ and parenting‐enhancement program (ProSAAF)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Information‐only control condition (self‐help materials)
Number of subjects: 331
Study: 22918898

Group type: EXPERIMENTAL
Intervention: Health & Safety Association (HSA) consultation
Number of subjects: 2153

Group type: EXPERIMENTAL
Intervention: Ministry of Labour (MOL) inspection
Number of subjects: 2153

Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 2153
Study: 21262673

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted inactivated fungal vaccine
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 18853114

Group type: EXPERIMENTAL
Intervention: Jisuikang (JSK)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (Conventional treatment)
Number of subjects: 84
Study: 15734602

Group type: EXPERIMENTAL
Intervention: MENQOL-Intervention questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MENQOL and MENQOL-Intervention questionnaires
Number of subjects: 0
Study: 12737092

Group type: EXPERIMENTAL
Intervention: Neurofeedback treatment (3-month electroencephalographic feedback program providing reinforcement contingent on the production of cortical sensorimotor rhythm (12-15 Hz) and beta activity (15-18 Hz))
Number of subjects: 34

Group type: COMPARATOR
Intervention: Methylphenidate (stimulant medication)
Number of subjects: 34
Study: 10471981

Group type: EXPERIMENTAL
Intervention: Tegaserod (12 mg oral dose) administered 30 minutes prior to meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tegaserod (12 mg oral dose) administered 15 minutes prior to meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tegaserod (12 mg oral dose) administered 1 minute before meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tegaserod (12 mg oral dose) administered 2.5 hours after meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tegaserod (12 mg oral dose) administered with a continued 4-hour postdose fast
Number of subjects: 18
Study: 8723588

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 150 IU/kg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 300 IU/kg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (both dosages)
Number of subjects: 31
Study: 1332526

Group type: EXPERIMENTAL
Intervention: Personal Involvement (PI) condition
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Relaxation (R) condition
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: No Treatment (NT) condition
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 6364908

Group type: EXPERIMENTAL
Intervention: Aminoglycosides (gentamicin and tobramycin)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Stepwise discriminant analysis
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Equation generated from discriminant analysis
Number of subjects: 214

Group type: COMPARATOR
Intervention: Factors not significantly contributing to nephrotoxicity risk
Number of subjects: 214
Study: 31764900

Group type: EXPERIMENTAL
Intervention: Natural food-based fiber solution
Number of subjects: 46
Study: 30196723

Group type: EXPERIMENTAL
Intervention: Monochromatic blue light exposure for 30 minutes
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control light (blue light with a filter foil) for 30 minutes
Number of subjects: 14
Study: 26892399

Group type: EXPERIMENTAL
Intervention: Echium oil (EO) 5 g ALA + 2 g SDA daily for 8 weeks
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Linseed oil (LO) 5 g ALA daily for 8 weeks
Number of subjects: 85

Group type: COMPARATOR
Intervention: Fish oil (FO)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Olive oil (OO)
Number of subjects: 85
Study: 23302145

Group type: EXPERIMENTAL
Intervention: Group-based parenting programme for parents of preschool children
Number of subjects: 0
Study: 22370992

Group type: EXPERIMENTAL
Intervention: Large doses of arachidonic acid (ARA) added to docosahexaenoic acid (DHA) (n = 7)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 13
Study: 20200197

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon beta-1a
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 17394956

Group type: EXPERIMENTAL
Intervention: Estradiol plus rapamycin-eluting stent (ERES)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Rapamycin-eluting stent (RES)
Number of subjects: 502
Study: 15644650

Group type: EXPERIMENTAL
Intervention: Tidal volume of 6 mL/kg predicted body weight
Number of subjects: 111

Group type: COMPARATOR
Intervention: Tidal volume of 12 mL/kg predicted body weight
Number of subjects: 111
Study: 11824860

Group type: EXPERIMENTAL
Intervention: Isotonic volume contraction (induced by furosemide infusion and replaced by 5% isotonic glucose infusion)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (salt-sensitive subjects)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (salt-resistant subjects)
Number of subjects: 24
Study: 10674679

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Artesunate-mefloquine
Number of subjects: 150
Study: 7744192

Group type: EXPERIMENTAL
Intervention: Inhaled methoxamine (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1963135

Group type: EXPERIMENTAL
Intervention: Isotretinoin (10 mg)
Number of subjects: 981

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 981
Study: 6291889

Group type: EXPERIMENTAL
Intervention: Cimetidine (200 mg IV bolus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine (0.12 mg/ml in vitro)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine (600 mg over 12 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg IV bolus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine (100 mg IV bolus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine and Ranitidine (in vitro antifibrinolytic effect)
Number of subjects: 0
Study: 31802740

Group type: EXPERIMENTAL
Intervention: Untreated obstructive sleep apnea (OSA)
Number of subjects: 287191

Group type: EXPERIMENTAL
Intervention: Inpatient care
Number of subjects: 287191

Group type: EXPERIMENTAL
Intervention: Prescriptions
Number of subjects: 287191

Group type: COMPARATOR
Intervention: Matched control patients without sleep-disordered breathing
Number of subjects: 287191
Study: 30019768

Group type: EXPERIMENTAL
Intervention: Active learning education program (weekly 90‐minute sessions for 24 weeks)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no active learning intervention)
Number of subjects: 84
Study: 27380049

Group type: COMPARATOR
Intervention: Laryngeal Tube LTS II™ size 2
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway Supreme™ size 2
Number of subjects: 56
Study: 24270967

Group type: EXPERIMENTAL
Intervention: Reverberation time of 0.7 s
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-reverberated condition
Number of subjects: 16
Study: 22289659

Group type: EXPERIMENTAL
Intervention: Oral PTH134 1 mg with 200 mg 5-CNAC
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral PTH134 2.5 mg with 200 mg 5-CNAC
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral PTH134 5 mg with 200 mg 5-CNAC
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral PTH134 10 mg with 200 mg 5-CNAC
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg sc
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral PTH134 2.5 mg with 100 mg 5-CNAC
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral PTH134 5 mg with 100 mg 5-CNAC
Number of subjects: 32
Study: 20584172

Group type: EXPERIMENTAL
Intervention: sFas levels in overweight/obese men (2.42 ng mL(‐1))
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: sFas levels in men with hyperlipidaemia (2.34 ng mL(‐1))
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: sFas levels in men with three to four metabolic risk factors (2.39 ng dL(‐1))
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: sFas levels in men with two metabolic risk factors (2.28 ng dL(‐1))
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: sFas levels in men with one metabolic risk factor (2.24 ng dL(‐1))
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: sFas levels in men with none of the four metabolic risk factors (2.11 ng dL(‐1))
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: sFas levels in women
Number of subjects: 876
Study: 17366526

Group type: EXPERIMENTAL
Intervention: Self-monitoring techniques (individualized counseling about fluid and caffeine intake, quick pelvic floor muscle contraction, voiding frequency, and management of constipation)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Self-monitoring techniques
Number of subjects: 224

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 224
Study: 15764328

Group type: EXPERIMENTAL
Intervention: Vibrotactile torso display with 15 tactor linear display
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vibrotactile torso display
Number of subjects: 0
Study: 12121537

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi Purpose Plus System (group I)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Single Bond adhesive (group II)
Number of subjects: 12
Study: 9867134

Group type: EXPERIMENTAL
Intervention: Fasting condition
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonfasting condition
Number of subjects: 40
Study: 7615030

Group type: EXPERIMENTAL
Intervention: Eyes-open condition
Number of subjects: 25

Group type: COMPARATOR
Intervention: Eyes-closed condition
Number of subjects: 25
Study: 2710995

Group type: EXPERIMENTAL
Intervention: Intestinal sterilization (n = 7)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Selective intestinal decontamination (n = 7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (Group II)
Number of subjects: 14
Study: 681526

Group type: EXPERIMENTAL
Intervention: Group treatment strategies
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control treatment strategy
Number of subjects: 239